Long-Acting Injectable PrEP for HIV: What Health Centers Need to Know

Current Status
Not Enrolled
Get Started

Long-acting injectable cabotegravir was approved for HIV pre-exposure prophylaxis in late 2021. In this interactive webinar, participants will learn about the effectiveness, advantages, and disadvantages of long-acting injectable cabotegravir as well as the clinical and programmatic steps to incorporate it into practice.